Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Short Bowel Syndrome 1Esophageal Squamous Cell Carcinoma 1Diarrhea 1Colorectal Neoplasms 1Colonic Neoplasms 1Colitis, Ulcerative 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 72Leucovorin 71Oxaliplatin 47Irinotecan 31Capecitabine 24Bevacizumab 23Folfox protocol 20Cetuximab 15Chemotherapy, Adjuvant 13Celecoxib 7Aspirin 6Laparoscopy 5XELOX 4Panitumumab 4Neoadjuvant Therapy 4Levamisole 4dehydroftorafur 3Tegafur 3Surgical Procedures, Operative 3Observation 3Floxuridine 3vatalanib 2tislelizumab 2pertuzumab 2encorafenib 2atezolizumab 2Trastuzumab 2Standard of Care 2Semaxinib 2Selenium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colonic Neoplasms × Loperamide × Clear all
NCT00003057 2023-06-18

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
500 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡